long intergenic non-protein coding RNA 1754Genealiases: []
Q-omics provides the consensus-scored LINC01754 profile across patient tissues and cancer cell-line models. LINC01754 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC01754 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, LINC01754 RNA expression shows 6,899 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, COAD, and STAD as cancer lineages where LINC01754 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01754 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01754 survival associations across molecular data types. LINC01754 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01754 RNA expression–survival associations across cancer types. High LINC01754 expression shows unfavorable associations in LGG, MESO and GBM, but favorable associations in LUAD, ESCA and CHOL. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC01754 RNA expression.
This table summarizes LINC01754 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01754. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01754 shows lower tumor expression in COAD, KICH and THCA and higher tumor expression in LIHC, CHOL and KIRP. The COAD box plot shows higher LINC01754 RNA expression in normal versus tumor tissue (log2 FC = −0.308, t-test p < 0.001).
This table shows molecular features associated with LINC01754 in patient tissues and cancer cell lines. In patient samples, LINC01754 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
